AI Article Synopsis
- Lateral flow assays (LFAs) are essential for fast, at-home diagnostics but typically only detect one biomarker at a time.
- There’s a growing need for multiplexed LFAs that can identify multiple biomarkers simultaneously due to the complexity of human diseases and the prevalence of co-infections.
- The text highlights challenges in designing and producing these advanced multiplexed systems and suggests areas for future research to improve infectious disease diagnostics.
Article Abstract
Lateral flow assays (LFAs) are the mainstay of rapid point-of-care diagnostics, with the potential to enable early case management and transform the epidemiology of infectious disease. However, most LFAs only detect single biomarkers. Recognizing the complex nature of human disease, overlapping symptoms and states of co-infections, there is increasing demand for multiplexed systems that can detect multiple biomarkers simultaneously. Due to innate limitations in the design of traditional membrane-based LFAs, multiplexing is arguably limited to a small number of biomarkers. Here, we summarize the need for multiplexed LFA, key technical and operational challenges for multiplexing, inherent in the design and production of multiplexed LFAs, as well as emerging enabling technologies that may be able to address these challenges. We further identify important areas for research in efforts towards developing multiplexed LFAs for more impactful diagnosis of infectious diseases.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5617951 | PMC |
| http://dx.doi.org/10.3390/diagnostics7030051 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!